JP4459435B2 - 新規ｔ細胞膜蛋白質（ｔｉｒｃ７）、ペプチドおよびそれに由来する抗体ならびにその使用 - Google Patents

新規ｔ細胞膜蛋白質（ｔｉｒｃ７）、ペプチドおよびそれに由来する抗体ならびにその使用 Download PDF

Info

Publication number
JP4459435B2
JP4459435B2 JP2000508792A JP2000508792A JP4459435B2 JP 4459435 B2 JP4459435 B2 JP 4459435B2 JP 2000508792 A JP2000508792 A JP 2000508792A JP 2000508792 A JP2000508792 A JP 2000508792A JP 4459435 B2 JP4459435 B2 JP 4459435B2
Authority
JP
Japan
Prior art keywords
cell
tirc7
leu
protein
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000508792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514852A5 (enExample
JP2001514852A (ja
Inventor
ナラン ウトゥク
スティーブン アール． グランス
エドガー エル． ミルフォード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19738710A external-priority patent/DE19738710A1/de
Application filed by Individual filed Critical Individual
Publication of JP2001514852A publication Critical patent/JP2001514852A/ja
Publication of JP2001514852A5 publication Critical patent/JP2001514852A5/ja
Application granted granted Critical
Publication of JP4459435B2 publication Critical patent/JP4459435B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2000508792A 1997-08-29 1998-08-28 新規ｔ細胞膜蛋白質（ｔｉｒｃ７）、ペプチドおよびそれに由来する抗体ならびにその使用 Expired - Lifetime JP4459435B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19738710A DE19738710A1 (de) 1997-08-29 1997-08-29 Verwendung von TIRC7 zur Herstellung von Mitteln zur Inhibition der Immunantwort
DE19738710.1 1997-08-29
DE29802653 1998-02-12
DE29802653.8 1998-02-12
PCT/EP1998/005462 WO1999011782A1 (en) 1997-08-29 1998-08-28 T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof

Publications (3)

Publication Number Publication Date
JP2001514852A JP2001514852A (ja) 2001-09-18
JP2001514852A5 JP2001514852A5 (enExample) 2006-01-05
JP4459435B2 true JP4459435B2 (ja) 2010-04-28

Family

ID=26039678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000508792A Expired - Lifetime JP4459435B2 (ja) 1997-08-29 1998-08-28 新規ｔ細胞膜蛋白質（ｔｉｒｃ７）、ペプチドおよびそれに由来する抗体ならびにその使用

Country Status (10)

Country Link
EP (2) EP0996726B1 (enExample)
JP (1) JP4459435B2 (enExample)
AT (1) ATE256185T1 (enExample)
AU (1) AU751151C (enExample)
CA (1) CA2301499C (enExample)
DE (1) DE69820449T2 (enExample)
DK (1) DK0996726T3 (enExample)
ES (1) ES2213295T3 (enExample)
PT (1) PT996726E (enExample)
WO (1) WO1999011782A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
AU2001263888A1 (en) * 2000-05-03 2001-11-12 Genpat77 Pharmacogenetics Ag Uses of tgap7 for the modulation of leucocyte activation
US20040072780A1 (en) * 2000-10-30 2004-04-15 Nalan Utku Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20050048067A1 (en) * 2001-09-17 2005-03-03 Nalan Utku Peptides capable of modulating immune response
EP1448227A2 (en) * 2001-11-27 2004-08-25 GenPat77 Pharmacogenetics AG Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
EP1492817A2 (en) * 2001-12-21 2005-01-05 GenPat77 Pharmacogenetics AG Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases
JP2005531282A (ja) 2001-12-21 2005-10-20 ゲンパト７７ ファーマコジェネティクス エージー 炎症性疾患の治療に用いる抗ｔｉｒｃ７抗体
EP1492555A2 (en) * 2002-02-04 2005-01-05 Nalan Utku Compositions and methods for modulation of effects on phagocyte and lymphoid cell population
US20050221424A1 (en) * 2002-04-26 2005-10-06 Nalan Utku Bispecific molecules for use in therapy and diagnosis of immune related and other diseases
WO2003093318A1 (en) * 2002-04-29 2003-11-13 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
CN101268373A (zh) * 2005-05-17 2008-09-17 塞尔艾克特制药有限公司 作为检测早期免疫激活的标记物的tirc7
WO2006122792A1 (en) * 2005-05-17 2006-11-23 Genpat77 Pharmacogenetics Ag Peptides capable of modulating the function of tirc7
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
CA3033645A1 (en) 2016-08-09 2018-02-15 Nekonal S.A.R.L. Tirc7 based diagnostic and therapy of cancer
CA3033620A1 (en) 2016-08-10 2018-02-15 Nekonal S.A.R.L. Tirc7 based diagnostic and therapy of solid cancer
US20220288120A1 (en) 2019-08-14 2022-09-15 Nekonal S.A.R.L. Method for producing engineered tirc7 specific t-regulatory cells (tregs)

Also Published As

Publication number Publication date
ES2213295T3 (es) 2004-08-16
CA2301499C (en) 2010-01-26
WO1999011782A1 (en) 1999-03-11
EP1350848A3 (en) 2004-02-04
ATE256185T1 (de) 2003-12-15
EP0996726B1 (en) 2003-12-10
EP1350848A2 (en) 2003-10-08
PT996726E (pt) 2004-04-30
EP0996726A1 (en) 2000-05-03
AU751151C (en) 2006-09-14
DE69820449T2 (de) 2005-03-10
JP2001514852A (ja) 2001-09-18
AU751151B2 (en) 2002-08-08
CA2301499A1 (en) 1999-03-11
DE69820449D1 (de) 2004-01-22
AU9265498A (en) 1999-03-22
DK0996726T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
JP4459435B2 (ja) 新規ｔ細胞膜蛋白質（ｔｉｒｃ７）、ペプチドおよびそれに由来する抗体ならびにその使用
US6338851B1 (en) Method of suppressing an immune response to a transplanted organ or tissue by administering an OX-2 protein
JP4169478B2 (ja) Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
JP4426724B2 (ja) Ｌｄｃａｍと称される分子
JPH09509826A (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
WO1995017506A9 (en) Mediators of chronic allograft rejection
WO1995017506A1 (en) Mediators of chronic allograft rejection
MXPA04003057A (es) Proteina 4 de enlace ul16.
WO2000019988A1 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
US7863418B2 (en) T-cell membrane protein (TIRC7) and peptides derived therefrom
WO1997021450A1 (en) Ox-2 costimulatory molecule
EP0795014A1 (en) Purified genes encoding mammalian cell surface antigens; proteins and antibodies
WO1995002611A1 (en) Cell surface protein present on nk (natural killer cells) named dx1
US20070212714A1 (en) Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof
EP1278535B1 (en) Uses of tgap7 for the modulation of leucocyte activation
US20030219424A1 (en) Novel T-cell protein (TZON7), peptides and antibodies derived therefrom and uses thereof
MXPA97003956A (en) Purified genes that codify antigens of surface of mammali cells, proteins and antibody
HK1159128B (en) Novel polypeptides involved in immune response
HK1159128A1 (en) Novel polypeptides involved in immune response
MXPA01007843A (en) Novel polypeptides involved in immune response
HK1159127B (en) Novel polypeptides involved in immune response
HK1160665A (en) Polypeptides involved in immune response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100114

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100210

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130219

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140219

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term